In the past few years, the discovery of epidermal growth factor receptor (EGFR) activating
mutations and the demonstration of efficacy of EGFR tyrosine kinase inhibitors (TKIs) have …

The discovery of activating mutations in epidermal growth factor receptor (EGFR) in non-
small-cell lung cancer transformed the care and prognosis of patients and heralded the era …

Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors
(TKIs) is highly effective in terms of tumor response rate, survival, and quality of life …

Tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor
(EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant …

Despite the improvement in clinical outcomes derived by the introduction of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have led to a
substantial improvement in the prognosis of lung cancer patients by explicitly targeting the …

The most common driver gene mutation in patients with non‐small‐cell lung cancer
(NSCLC) is an epidermal growth factor receptor (EGFR) mutation. With the introduction of …

The introduction of first-and second-generation EGFR-tyrosine kinase inhibitors
(TKIs)(gefitinib, erlotinib and afatinib) for the treatment of advanced EGFR-mutant non-small …

Epidermal growth factor receptor (EGFR) mutations (EGFRm+) occur in 10–35% of non-
small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase …

The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung
cancer and the subsequent discovery of activating EGFR mutations have led to an explosion …